Biogen scraps two late-stage Alzheimer's trials

(Reuters) – Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer’s disease. The companies said the decision was based on the results of a safety review conducted by a data safety monitoring board, which recommended to discontinue the trials due to unfavorable risk-benefit ratio. The announcement comes months after the companies said they were ending two late-stage trials of another experimental Alzheimer’s disease drug, aducanumab. The company’s shares fell 1.6% to $228.50 in premarket trading.

Leave a Reply

Your email address will not be published. Required fields are marked *